Maseroli, E.
Verde, N.
Cipriani, S.
Rastrelli, G.
Alfaroli, C.
Ravelli, S. A.
Costeniero, D.
Scairati, R.
Minnetti, M.
Petraglia, F.
Auriemma, R. S.
Nappi, R. E.
Maggi, M.
Vignozzi, L. http://orcid.org/0000-0003-0907-0630
Funding for this research was provided by:
UniversitĂ degli Studi di Firenze
Article History
Received: 4 January 2023
Accepted: 19 April 2023
First Online: 18 May 2023
Declarations
:
: LV received scientific research grants, advisory board attendance and speaker honoraria from Therascience, Theramex, Bayer Schering Pharma, Intercept, Lipocine, Ibsa. REN had past financial relationships (lecturer, member of advisory boards and/or consultant) with Boehringer Ingelheim, Ely Lilly, Endoceutics, Gedeon Richter, HRA Pharma, Merck Sharpe & Dohme, Procter & Gamble Co, TEVA Women’s Health Inc and Zambon SpA. At present, she has ongoing relationship with Astellas, Bayer HealthCare AG, Exceltis, Fidia, Novo Nordisk, Organon & Co, Palatin Technologies, Pfizer Inc, Shionogi Limited and Theramex. None of these companies are relevant to the present work.EM, NV, SC, GR, CA, DC, RS, MM, FP, RSA, and MM have nothing to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved by the local ethics committee (protocol 37.589/SPE.13.034, Careggi Hospital, Florence, Italy).
: Informed consent was obtained from all individual participants included in the study.